<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Urmila M Aswar</style></author><author><style face="normal" font="default" size="100%">Savita R. Nimse</style></author><author><style face="normal" font="default" size="100%">Prasad A. Thakurdesai</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Androgenic Efficacy and Mechanism of Glycosides-Based  Standardized Fenugreek Seeds Extract Through Aromatase And  5-Alpha Reductase Inhibition</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Androgenic</style></keyword><keyword><style  face="normal" font="default" size="100%">Fenugreek extract</style></keyword><keyword><style  face="normal" font="default" size="100%">Glycosides</style></keyword><keyword><style  face="normal" font="default" size="100%">Sexual Behavior</style></keyword><keyword><style  face="normal" font="default" size="100%">Spermatogenic</style></keyword><keyword><style  face="normal" font="default" size="100%">Testosterone</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style  face="normal" font="default" size="100%">February</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">16</style></volume><pages><style face="normal" font="default" size="100%">09-19</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Introduction:&lt;/strong&gt; Fenugreek seeds glycosides content have many health benefits. &lt;strong&gt;Objective:&lt;/strong&gt; To evaluate the androgenic efficacy and probable mechanism of glycosides-based standardized fenugreek seed extract (SFSE-G) in laboratory rats. &lt;strong&gt;Methods:&lt;/strong&gt; Male Wistar rats were administrated with 28-days of once-daily oral administration of SFSE-G (10 or 35 mg/kg) on sexual and orientational behavior with female rats, serum testosterone concentrations, weights of reproductive system-related organs (seminal vesicles, prostate, levator ani), nitric oxide level in penis homogenate, sperm count in the cauda epididymis, and testis histology were evaluated. Separate groups of rats with a positive control (testosterone propionate (10 mg/ kg, s.c. bi-weekly) and vehicle control (distilled water) were maintained. In addition, the safety of acute intravenous administration of SFSE-G (1 mg/kg) on cardiovascular function parameters was evaluated. Moreover, the inhibitory potential of SFSE-G against aromatase and 5-alpha-reductase enzymes was evaluated in vitro. &lt;strong&gt;Results:&lt;/strong&gt; Subacute administration of SFSE-G (35 mg/kg, oral) to male rats showed androgenic efficacy in sexual behavior (increased mounting and intromission latency and rearing), with increased weights of seminal vehicles, prostate and levator ani muscles, serum testosterone levels, sperm count, and penile NO concentration, while preserving the normal architecture of the testes. Acute intravenous administration of SFSE-G to rats increased intracavernous pressure but retained normal cardiovascular parameters, such as blood pressure, heart rate, and corrected QT interval (QTc). SFSE-G showed significant inhibition of aromatase and 5-alpha-reductase in vitro. &lt;strong&gt;Conclusion:&lt;/strong&gt; SFFE-G exhibited significant androgenic and spermatogenic efficacy, mediated through testosterone metabolism inhibition, without affecting the cardiovascular system in laboratory rats.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue><work-type><style face="normal" font="default" size="100%">Original Article</style></work-type><section><style face="normal" font="default" size="100%">09</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Urmila M Aswar&lt;sup&gt;1&lt;/sup&gt;, Savita R. Nimse&lt;sup&gt;2&lt;/sup&gt;, Prasad A. Thakurdesai&lt;sup&gt;2&lt;/sup&gt;,&lt;sup&gt;*&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Department of Pharmacology, Poona College of Pharmacy, Bharati Vidyapeeth Deemed University, Pune, INDIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Department of Scientific affairs, Indus Biotech Limited, 1, Rahul Residency, Off Salunke Vihar Road, Kondhwa, Pune 411048, INDIA.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Prasad A. Thakurdesai</style></author><author><style face="normal" font="default" size="100%">Pallavi O. Deshpande</style></author><author><style face="normal" font="default" size="100%">Mukul P. Pore</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Characterization, Preclinical Efficacy and Toxicity Evaluations of Flavonoids Glycosides based Standardized Fenugreek Seed Extract (FEFLG)</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Acute toxicity</style></keyword><keyword><style  face="normal" font="default" size="100%">CD38+ enzyme inhibition</style></keyword><keyword><style  face="normal" font="default" size="100%">Chromosomal aberration.</style></keyword><keyword><style  face="normal" font="default" size="100%">Fenugreek seeds</style></keyword><keyword><style  face="normal" font="default" size="100%">Flavonoid glycosides</style></keyword><keyword><style  face="normal" font="default" size="100%">Mutagenicity</style></keyword><keyword><style  face="normal" font="default" size="100%">Subchronic Toxicity</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">March 2023</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">15</style></volume><pages><style face="normal" font="default" size="100%">90-105</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Introduction: &lt;/strong&gt;Fenugreek seeds, a natural food chain raw material, is known to have many flavonoid glycosides. &lt;strong&gt;Objective:&lt;/strong&gt; Characterization, preclinical efficacy, and safety evaluation of flavonoid glycosidebased standardized fenugreek seed extract (FEFLG). &lt;strong&gt;Methods:&lt;/strong&gt; FEFLG was characterized for a group of flavonoid glycoside marker compounds by HPLC. The CD38+ enzyme inhibition efficacy was assessed &lt;em&gt;in vitro.&lt;/em&gt; In addition, acute oral toxicity (AOT) and subchronic, 90-day repeated-dose oral toxicity (&lt;em&gt;in vivo&lt;/em&gt;), mutagenicity (AMES test, &lt;em&gt;in vitro&lt;/em&gt;) and chromosome aberration test (&lt;em&gt;in vitro&lt;/em&gt;) of FEFLG were evaluated. &lt;strong&gt;Results&lt;/strong&gt;: The FEFLG was found to have 49.85% of total flavonoid glycosides content in FEFLG (25.15% of Group 1: vitexin, isovitexin and vitexin 2-o- rhamnoside and 24.70% of Group 2 (vicenin derivatives, schaftoside, iso-schaftoside, orientin and iso-orientin). FEFLG showed CD38+ enzyme inhibition&lt;em&gt; in vitro&lt;/em&gt; (IC50= 0.96 μg/ml) equivalent to the positive control, apigenin. FEFLG did not show any toxicity at an acute oral dose of more than 2000 mg/kg (median lethal dose, LD50) with a limit dose of 5000 mg/kg. The 90-day repeated-dose oral administration of FEFLG did not induce significant toxicological changes till the maximum dose of 1000 mg/kg in male and female rats, indicating no observed adverse effect level, NOAEL ≥ 1000 mg/kg. FEFLG did not show mutagenicity (up to a concentration of 5000 μg/plate) or structural chromosomal aberrations (up to 5000 μg /ml). &lt;strong&gt;Conclusion:&lt;/strong&gt; The CD38+ enzyme inhibitor efficacy&lt;em&gt; in vitro&lt;/em&gt;, oral safety &lt;em&gt;in vivo&lt;/em&gt; and absence of mutagenicity or genotoxicity of FEFLG indicated its potential for anti-aging applications.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue><work-type><style face="normal" font="default" size="100%">Original Article </style></work-type><section><style face="normal" font="default" size="100%">90</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p&gt;&lt;strong&gt;Prasad A. Thakurdesai*, Pallavi O. Deshpande, Mukul P. Pore&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Indus Biotech Limited, Pune, INDIA.&lt;/p&gt;
</style></auth-address></record></records></xml>